公开(公告)号：EP3253734A4

公开(公告)日：2018-07-25

申请号：EP16747042

申请日：2016-02-01

申请人： UNIV MICHIGAN REGENTS

发明人： LARSEN SCOTT D ,  ABE AKIRA ,  SHU LIMING ,  WILSON MICHAEL WILLIAM ,  KEEP RICHARD F ,  SUN DUXIN ,  SHAYMAN JAMES A

IPC分类号： C07D207/04 ,  A61K31/401 ,  A61K31/421 ,  A61P25/00 ,  A61P25/28 ,  C07D205/04 ,  C07D263/20 ,  C07D263/24

CPC分类号： C07D207/06 ,  C07D205/04 ,  C07D207/04 ,  C07D207/09 ,  C07D207/10 ,  C07D263/20 ,  C07D263/24 ,  C07D295/125 ,  C07D295/13

摘要： Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.

公开(公告)号：EP3229817A4

公开(公告)日：2018-06-20

申请号：EP15867330

申请日：2015-12-11

申请人： COMMW SCIENT IND RES ORG

发明人： NILSSON SUSAN KAYE ,  HAYLOCK DAVID NORMAN ,  CAO BENJAMIN BEN MING

IPC分类号： A61K35/28 ,  A61K31/401 ,  A61P35/00 ,  A61P35/02

CPC分类号： A61K38/05 ,  A61K31/395 ,  A61K31/401 ,  A61K31/4439 ,  A61K35/28 ,  A61K45/06 ,  A61P35/02 ,  A61K2300/00

摘要： Haematopoietic stem cell mobilization is a process whereby haematopoietic stem cells are stimulated out of the bone marrow space. Before HSC can mobilize, they must be dislodged and released from the BM stem cell niche in which they reside and are retained by adhesive interactions. Accordingly, in an aspect of the present invention there is provided a method for enhancing dislodgement of HSC and their precursors and progenitors thereof from a BM stem cell binding ligand in vivo or ex vivo, said method comprising administering in vivo or ex vivo an effective amount of an antagonist of an α9 integrin or an active portion thereof and a CXCR4 antagonist or an active portion thereof to the BM stem cell niche. Once mobilized to the peripheral blood (PB) the HSC may be collected for transplant. Methods which enhance mobilization of the HSC can also improve treatments of haematological disorders.

公开(公告)号：EP2504001B8

公开(公告)日：2018-06-06

申请号：EP10790906.1

申请日：2010-11-25

申请人： Professional Dietetics International S.r.l. in forma abbreviata P.D. INT. S.R.L.

发明人： CONTI, Edoardo, Carlo, Maria ,  CONTI, Giovanni, Federico, Maria ,  ARBORIO MELLA, Isabella ,  DIOGUARDI, Francesco, Saverio

IPC分类号： A61K31/198 ,  A61K31/728 ,  A61P1/02 ,  A61K45/06 ,  A61K31/401

CPC分类号： A61K31/728 ,  A61K9/0053 ,  A61K31/138 ,  A61K31/198 ,  A61K31/401 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to the use of a combination of glycine, proline, and optionally a natural or synthetic film-forming polymer, and/or lysine and/or leucine, to prepare a composition for the treatment of mucositis induced by radiation or chemotherapy.

公开(公告)号：EP3212619A4

公开(公告)日：2018-05-30

申请号：EP15855693

申请日：2015-10-26

申请人： MERCK SHARP & DOHME

发明人： DING FA-XIANG ,  DONG SHUZHI ,  JIANG JINLONG ,  SUZUKI TAKAO ,  VACCA JOSEPH P ,  XU SHOUNING

IPC分类号： C07D471/10 ,  A61K31/401 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/435 ,  A61K31/4422 ,  A61K31/55 ,  A61P9/10 ,  A61P9/12 ,  A61P13/12

CPC分类号： C07D471/10 ,  A61K31/401 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/435 ,  A61K31/4422 ,  A61K31/444 ,  A61K31/501 ,  A61K31/55 ,  A61K2300/00

摘要： The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

公开(公告)号：EP2859891B1

公开(公告)日：2018-02-21

申请号：EP14187915.5

申请日：2014-10-07

申请人： Professional Dietetics S.p.A. in forma abbreviata "P.D. S.p.A."

发明人： Giorgetti, Paolo

IPC分类号： A61K31/198 ,  A61K31/401 ,  A61K47/32 ,  A61K31/717 ,  A61K31/728 ,  A61K47/36 ,  A61K47/38 ,  A61K9/00 ,  A61P1/04

CPC分类号： A61K31/401 ,  A61K9/006 ,  A61K31/198 ,  A61K31/717 ,  A61K31/728 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38 ,  A61K2300/00

摘要： The present invention relates to the use of a combination of glycine, proline, and optionally a natural or synthetic film-forming polymer, and/or lysine and/or leucine, for the preparation of a composition for the prevention of mucositis induced by radiation or chemotherapy.

公开(公告)号：EP3231437A4

公开(公告)日：2018-01-17

申请号：EP15868543

申请日：2015-12-01

申请人： NIHON SIZEN HAKKOH CO LTD

发明人： HIGASHI NAOKI ,  NAKANISHI MASAHIRO

IPC分类号： A61K36/07 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/196 ,  A61K31/197 ,  A61K31/198 ,  A61K31/352 ,  A61K31/353 ,  A61K31/401 ,  A61K31/405 ,  A61K31/4172 ,  A61K35/744 ,  A61K36/03 ,  A61K36/062 ,  A61K36/064 ,  A61K36/185 ,  A61K36/31 ,  A61K36/39 ,  A61K36/75

CPC分类号： A61K31/198 ,  A23K10/12 ,  A23K50/50 ,  A23L2/52 ,  A23L33/105 ,  A23V2002/00 ,  A61K8/99 ,  A61K31/19 ,  A61K31/192 ,  A61K31/194 ,  A61K31/196 ,  A61K31/197 ,  A61K31/352 ,  A61K31/353 ,  A61K31/401 ,  A61K31/405 ,  A61K31/4172 ,  A61K35/744 ,  A61K36/03 ,  A61K36/062 ,  A61K36/064 ,  A61K36/07 ,  A61K36/16 ,  A61K36/185 ,  A61K36/23 ,  A61K36/28 ,  A61K36/282 ,  A61K36/31 ,  A61K36/39 ,  A61K36/42 ,  A61K36/44 ,  A61K36/48 ,  A61K36/49 ,  A61K36/52 ,  A61K36/535 ,  A61K36/60 ,  A61K36/605 ,  A61K36/73 ,  A61K36/736 ,  A61K36/75 ,  A61K36/752 ,  A61K36/78 ,  A61K36/81 ,  A61K36/87 ,  A61K36/88 ,  A61K36/888 ,  A61K36/8945 ,  A61K36/8962 ,  A61K36/8967 ,  A61K36/899 ,  A61K36/8994 ,  A61K36/8998 ,  A61K36/9066 ,  A61K36/9068

摘要： An object of the present invention is to provide a senescence retarding agent that delays the onset of senescence symptoms and extends longevity, and is superior in safety. The senescence retarding agent of the present invention that achieves the object is characterized by containing a plant fermentation product as an active ingredient, the plant fermentation product being a mixture of the following: (a) a koji mold-fermented product of one or more kinds of beans and/or cereals selected from the group consisting of barley, black soybean, red rice, black rice, adzuki bean, adlay, Japanese millet, foxtail millet, and millet; (b) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of fruits selected from the group consisting of mikan (mandarin orange), grape, apple, yama-budo (crimson glory grape), peach, kaki (Japanese persimmon), papaya, nashi (Japanese pear), watermelon, ume (Japanese apricot), fig, karin (Chinese quince), pumpkin, kumquat, yuzu (Chinese lemon), loquat, apricot, jujube, chestnut, matatabi (silvervine), and sumomo (Japanese plum) ; (c) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of root crops and/or potatoes selected from the group consisting of murasaki-imo (purple sweet potato), kikuimo (Jerusalem artichoke), carrot, onion, satsuma-imo (sweet potato), satoimo (taro), jinenzyo (Japanese yam), daikon (Japanese radish), akakabu (red turnip), gobo (burdock root), renkon (lotus root), yacon, yuri-ne (lily bulb), kuwai (arrowhead), ginger, garlic, and turmeric; (d) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of flowers and/or leaf vegetables selected from the group consisting of cabbage, shiso (perilla), mulberry leaves, dokudami (Korean houttuynia), yomogi (wormwood), kumazasa (kuma bamboo grass), and dandelion; (e) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of seaweeds selected from the group consisting of kombu (sea tangle), wakame (Undaria pinnatifida), and mozuku (Nemacystus decipiens); (f) a yeast- and/or lactic acid bacterium-fermented product of one or more kinds of seeds selected from the group consisting of black sesame seeds, walnuts, and ginkgo nuts; and (g) a yeast- and/or lactic acid bacterium-fermented product of one or two kinds of mushrooms selected from the group consisting of maitake (Grifola frondosa) and shiitake (Lentinus edodes).

公开(公告)号：EP1575558B1

公开(公告)日：2017-11-08

申请号：EP03814501.7

申请日：2003-12-26

申请人： Thorel, Jean-Noël

发明人： THOREL, Jean-Noël ,  GATTO, Hugues

IPC分类号： A61K9/00 ,  A61K45/06 ,  A61K47/02 ,  A61K47/18 ,  A61K31/401 ,  A61K31/728

CPC分类号： A61K9/0014 ,  A61K9/0048 ,  A61K31/401 ,  A61K31/728 ,  A61K45/06 ,  A61K47/02 ,  A61K47/18 ,  Y02A50/471 ,  A61K2300/00

公开(公告)号：EP3110423A4

公开(公告)日：2017-09-20

申请号：EP15755233

申请日：2015-02-25

申请人： ACHILLION PHARMACEUTICALS INC

发明人： GADHACHANDA VENKAT RAO ,  PAIS GODWIN ,  HASHIMOTO AKIHIRO ,  WANG QIUPING ,  CHEN DAWEI ,  WANG XIANGZHU ,  AGARWAL ATUL ,  DESHPANDE MILIND ,  PHADKE AVINASH S ,  WILES JASON ALLAN

IPC分类号： C07D401/14 ,  A61K31/401 ,  A61K31/416 ,  A61P37/00 ,  C07D405/14 ,  C07D413/14

CPC分类号： C07F9/5728 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/0053 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/4192 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/549 ,  A61K31/55 ,  A61K31/675 ,  A61K31/683 ,  C07B59/002 ,  C07B2200/05 ,  C07D209/12 ,  C07D209/14 ,  C07D209/30 ,  C07D209/40 ,  C07D209/42 ,  C07D209/44 ,  C07D209/88 ,  C07D401/14 ,  C07D403/06 ,  C07D403/08 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D487/04 ,  C07D487/14 ,  C07D491/113 ,  C07D495/04 ,  C07D513/04 ,  C07F5/025 ,  C07F5/027 ,  C07F7/0812 ,  C07F9/65583 ,  C07F9/6561 ,  C07F9/65616

摘要： Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

摘要翻译： 提供了包含式I的补体因子D抑制剂或其药学上可接受的盐或组合物，其中A基团上的R 12或R 13是氨基取代基（R 32）的化合物，使用方法和方法。 本文描述的抑制剂靶向因子D并在替代补体途径的早期和必需点抑制或调节补体级联并降低因子D调节经典和凝集素补体途径的能力。 本文描述的因子D的抑制剂能够减少已经与某些自身免疫疾病，炎性疾病和神经退行性疾病以及缺血再灌注损伤和癌症相关的补体的过度激活。

公开(公告)号：EP1629840B1

公开(公告)日：2017-08-16

申请号：EP04735515.1

申请日：2004-05-31

申请人： RIKEN ,  Meiji Co., Ltd.

发明人： ABE, Takashi ,  SAWAI, Yasuko c/o MEIJI DAIRIES COPORATION

IPC分类号： A61P3/02 ,  A61K31/198 ,  A61K31/401 ,  A61K31/405 ,  A61K31/4172 ,  A23L33/175

CPC分类号： A61K31/401 ,  A23L33/175 ,  A61K31/198 ,  A61K31/405 ,  A61K31/4172 ,  A61K2300/00

公开(公告)号：EP3200785A1

公开(公告)日：2017-08-09

申请号：EP15790624.9

申请日：2015-10-02

申请人： Convergence Pharmaceuticals Limited

发明人： MORISSET, Valerie

IPC分类号： A61K31/401 ,  C12Q1/68 ,  A61P25/02 ,  A61P29/00

CPC分类号： A61K31/401 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156

摘要： The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.

摘要翻译： 本发明涉及治疗阵发性极端疼痛病症（PEPD），包括向有需要的受试者施用治疗有效量的5-（4 - {[（2-氟苯基）甲基]氧基}苯基） - 脯氨酰胺 或其药学上可接受的盐，溶剂化物或前药。